"There may be more deals on the way. Eli Lilly and Novo Nordisk have already reduced prices for the leading GLP-1s in their recent agreement with President Trump in exchange for expanded access to millions of people on Medicare. Medical researchers also continue to find promising new medical uses for GLP-1s, including treatment of addiction, COPD and dementia - though not every application has proven successful."
"By the numbers: 1 in 8 Americans say they're currently taking a GLP-1 such as Ozempic or Wegovy either to lose weight or treat a chronic condition, per KFF. While most say their insurance picked up at least some of the cost, about a quarter (27%) report they paid the full cost themselves. 3 in 4 say they got the drugs they took from one of their doctors, while about 1 in 6 (17%) say they got them from an online provider or website."
"Yes, but: The drugs still come with unpleasant side effects like nausea, vomiting and diarrhea that lead many people to quit. In most of those cases, their weight returns. Physicians note that many patients start GLP-1s to treat obesity without proper counseling from a health provider about diet and exercise and how to manage the side effects. The drugs' potential beyond weight loss and diabetes still isn't fully clear."
Eli Lilly and Novo Nordisk reduced prices for leading GLP-1 drugs as part of an agreement that expands Medicare access to millions. Eli Lilly's GLP-1 Zepbound helped push the company to a $1 trillion market valuation. Both companies plan to sell GLP-1s directly to employers and are developing oral formulations that avoid injections. One in eight Americans reports using a GLP-1, with most receiving some insurance coverage but 27% paying full cost; 75% obtained drugs from doctors and 17% from online sources. The drugs cause nausea, vomiting and diarrhea, often leading to discontinuation and weight regain. Novo Nordisk's Rybelsus failed to slow Alzheimer's progression, while researchers explore other indications like addiction, COPD and dementia.
#glp-1-drugs #drug-pricing-and-medicare #side-effects-and-discontinuation #clinical-trials-and-new-indications
Read at Axios
Unable to calculate read time
Collection
[
|
...
]